Bio Historical Cash Flow
| BIO Stock | USD 336.09 3.18 0.96% |
Analysis of Bio Rad cash flow over time is an excellent tool to project Bio Rad Laboratories future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 271.2 M or Other Cashflows From Financing Activities of 3.4 M as it is a great indicator of Bio Rad ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Bio Rad Laboratories latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bio Rad Laboratories is a good buy for the upcoming year.
Bio |
About Bio Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Bio balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Bio's non-liquid assets can be easily converted into cash.
Bio Rad Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Change Receivables
The difference in the amount of accounts receivable from one accounting period to the next. A positive number indicates an increase in receivables, while a negative number indicates a decrease.Most accounts from Bio Rad's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Bio Rad Laboratories current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. At this time, Bio Rad's Change To Account Receivables is very stable compared to the past year. As of the 25th of November 2024, Change Receivables is likely to grow to about 82.3 M, though Change To Inventory is likely to grow to (44 M).
Bio Rad cash flow statement Correlations
Click cells to compare fundamentals
Bio Rad Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bio Rad cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 24.2M | (52.1M) | 46.1M | (158.8M) | (46.3M) | (44.0M) | |
| Change In Cash | 228.5M | 4.5M | (196.0M) | (36.6M) | (30.2M) | (28.7M) | |
| Free Cash Flow | 359.4M | 476.4M | 535.7M | 80.3M | 218.3M | 229.2M | |
| Change In Working Capital | 55.4M | 51.7M | 13.9M | (407.0M) | (127.6M) | (121.3M) | |
| Begin Period Cash Flow | 434.2M | 662.7M | 667.1M | 471.1M | 434.5M | 271.2M | |
| Other Cashflows From Financing Activities | 5.9M | 3.9M | (2.4M) | (212.1M) | 3.5M | 3.4M | |
| Depreciation | 134.2M | 138.1M | 133.8M | 137.3M | 192.4M | 202.0M | |
| Other Non Cash Items | (1.5B) | (3.4B) | (3.7B) | 5.3B | 1.1B | 1.1B | |
| Capital Expenditures | 98.5M | 98.9M | 120.8M | 114.2M | 156.7M | 84.5M | |
| Total Cash From Operating Activities | 457.9M | 575.3M | 656.5M | 194.4M | 374.9M | 393.7M | |
| Net Income | 1.8B | 3.8B | 4.2B | (3.6B) | (637.3M) | (605.5M) | |
| Total Cash From Financing Activities | (22.8M) | (523.0M) | (55.4M) | 973.6M | (425.6M) | (404.4M) | |
| End Period Cash Flow | 662.7M | 667.1M | 471.1M | 434.5M | 404.4M | 286.4M | |
| Sale Purchase Of Stock | (28M) | (100.0M) | (50.0M) | (215.7M) | (428.7M) | (407.3M) | |
| Stock Based Compensation | 35.6M | 41.6M | 51.2M | 60.9M | 61.3M | 64.4M | |
| Total Cashflows From Investing Activities | (208.9M) | (60.3M) | (784.4M) | (1.2B) | (1.1B) | (1.0B) | |
| Other Cashflows From Investing Activities | 129K | (80.9M) | (658.9M) | (100.6M) | (90.5M) | (95.1M) | |
| Change To Netincome | (2.0B) | (3.5B) | (3.8B) | 5.3B | 4.7B | 5.0B | |
| Change To Account Receivables | 1.6M | (15M) | (20.4M) | (87.4M) | 11.4M | 12.0M | |
| Change Receivables | 31.7M | 21.5M | 35.3M | 68.2M | 78.4M | 82.3M | |
| Net Borrowings | (1.1M) | (426.9M) | (3.0M) | 1.2B | 1.4B | 1.4B | |
| Exchange Rate Changes | (655K) | 2.2M | 12.4M | (12.6M) | (11.4M) | (10.8M) | |
| Cash And Cash Equivalents Changes | 228.5M | 4.5M | (196.0M) | (39.6M) | (35.6M) | (33.8M) | |
| Investments | (119.3M) | 119.6M | (538.2M) | (994.2M) | (110.5M) | (116.1M) | |
| Cash Flows Other Operating | 426.2M | 553.8M | 621.2M | 126.3M | 145.2M | 137.9M | |
| Change To Operating Activities | 73.5M | 51.7M | 13.9M | (26.8M) | (30.8M) | (29.3M) | |
| Change To Liabilities | 460.8M | 1.1B | 1.2B | (1.3B) | (1.5B) | (1.5B) |
Pair Trading with Bio Rad
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Rad position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Rad will appreciate offsetting losses from the drop in the long position's value.Moving against Bio Stock
| 0.4 | VCNX | Vaccinex | PairCorr |
| 0.4 | FBRX | Forte Biosciences Trending | PairCorr |
| 0.38 | VALN | Valneva SE ADR | PairCorr |
| 0.35 | HLN | Haleon plc | PairCorr |
The ability to find closely correlated positions to Bio Rad could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Rad when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Rad - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Rad Laboratories to buy it.
The correlation of Bio Rad is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Rad moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Rad Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Rad can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.412 | Earnings Share (28.06) | Revenue Per Share 90.815 | Quarterly Revenue Growth 0.028 | Return On Assets 0.0186 |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.